ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2019
Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy.The journal of allergy and clinical immunology. In practice · 2022Trial
- Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE.The Journal of allergy and clinical immunology · 2020Trial
- Immunization with Virus-Like Particles Displaying Ara h 2‑Derived Peptides to Mitigate Peanut Allergy.ACS nano medicine · 2026Article
- Article
- Safety and Efficacy of Very Low-Dose Multi-Nut Oral Immunotherapy in Children.Clinical and translational allergy · 2025Article
- Epitope-Specific Antibodies in Allergic Disease and Clinical Tolerance.Immunological reviews · 2025Review
- Pru p 3-specific IgE affinity is crucial in severe peach-allergy patients.The World Allergy Organization journal · 2024Article
- Low-dose oral immunotherapy in immunoglobulin E-mediated food allergies.Frontiers in immunology · 2024Review
- Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy.The Journal of clinical investigation · 2023Article
- IgE and IgG4 epitopes of the peanut allergens shift following oral immunotherapy.Frontiers in allergy · 2023Article
- Associations between food-specific IgG and health outcomes in an asymptomatic physical examination cohort.Nutrition & metabolism · 2022Article
- The Road Toward Transformative Treatments for Food Allergy.Frontiers in allergy · 2022Review
- Induction of food-specific IgG by Gene Gun-delivered DNA vaccines.Frontiers in allergy · 2022Article
- Pathogenesis of IgE-mediated food allergy and implications for future immunotherapeutics.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021Review
- Mechanisms of oral immunotherapy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Review
- Effectiveness and safety of oral lactococci-based vaccine encoding triple common allergens to prevent airway allergy in mice.PloS one · 2021Article
- From Allergen Molecules to Molecular Immunotherapy of Nut Allergy: A Hard Nut to Crack.Frontiers in immunology · 2021Review
- Evolution of Immune Responses in Food Immunotherapy.Immunology and allergy clinics of North America · 2020Review
- IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy.Frontiers in immunology · 2020Review
- Immunological Outcomes of Allergen-Specific Immunotherapy in Food Allergy.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOral and sublingual immunotherapies for peanut allergy have demonstrated efficacy in small clinical trials; however, mechanisms and biomarkers correlating with clinical outcomes remain elusive. Previous studies have demonstrated a role for IgG in post-OIT plasma in the suppression of IgE-mediated mast cell reactions.
objectiveThe aim of this study was to characterize the role that peanut oral and sublingual immunotherapy-induced plasma factors play in the inhibition of ex vivo basophil activation and whether inhibitory activity is associated with clinical outcomes.
methodsPlasma samples from subjects on placebo, peanut oral immunotherapy (OIT) or peanut sublingual immunotherapy (SLIT), and IgG-depleted plasma or the IgG fraction were incubated with sensitized basophils, and the inhibition of basophil activation following stimulation with peanut extract was measured. Basophil inhibition results were compared between the two routes of immunotherapy, time on treatment and clinical outcomes.
resultsPlasma from subjects after 12 months of active peanut OIT, but not placebo, inhibits basophil activation ex vivo. Depletion of IgG abrogated the blocking effect of OIT plasma, while the IgG fraction substantially blocked basophil activation. Basophils are inhibited to a similar extent by undiluted OIT and SLIT plasma; however, diluted OIT plasma from the time of desensitization challenge inhibited basophils more than diluted SLIT plasma from time of desensitization challenge. Plasma from subjects who experienced sustained unresponsiveness following OIT inhibited basophils to a greater extent than plasma from subjects who were desensitized, but this was not true for SLIT. CONCLUSIONS AND CLINICAL RELEVANCE: Peanut immunotherapy induces IgG-dependent functional changes in plasma that are associated with OIT but not SLIT clinical outcomes. Understanding the mechanisms of peanut OIT and SLIT may help derive informative biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.